Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: A phase I trial

Gene Therapy

Volumn 8, Issue 21, 2001, Pages 1618-1626

  Reid, T ^a   Galanis, E ^b   Abbruzzese, J ^c   Sze, D ^a   Andrews, J ^b   Romel, L ^d   Hatfield, M ^d   Rubin, J ^b   Kirn, D ^e  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b MAYO CLINIC   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d ONYX PHARMACEUTICALS   (United States)

^e IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

Adenovirus; Cancer; Clinical trial; Colorectal carcinoma; Gene therapy; Replication competent

Indexed keywords

ANTINEOPLASTIC AGENT; FLUOROURACIL; FOLINIC ACID; NEUTRALIZING ANTIBODY; ONYX 015; UNCLASSIFIED DRUG; VIRUS VECTOR;

ABDOMINAL PAIN; ADENOVIRUS; ADULT; AGED; ANOREXIA; ANTIBODY TITER; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CARCINOMA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG TOLERABILITY; FATIGUE; FEMALE; FEVER; GASTROINTESTINAL CARCINOMA; GENETIC ENGINEERING; GRANULOCYTOSIS; HEMATOLOGIC DISEASE; HEPATIC ARTERY; HUMAN; LIVER METASTASIS; LIVER TOXICITY; LYMPHOCYTOSIS; MALE; METABOLIC DISORDER; MOUTH ULCER; MYALGIA; NAUSEA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RIGOR; STOMATITIS; VIRUS ATTENUATION; VIRUS REPLICATION; VOMITING;

ADENOVIRIDAE; ADENOVIRUS E1B PROTEINS; AGED; ANTIBODIES, VIRAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; FEMALE; FLUOROURACIL; GENE DELETION; GENE THERAPY; GENOME, VIRAL; HEPATIC ARTERY; HUMANS; INFUSIONS, INTRA-ARTERIAL; LEUCOVORIN; LIVER NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; VIRUS REPLICATION;

ADENOVIRIDAE; ONYX;

EID: 0035177690     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3301512     Document Type: Article

References (38)

1. Gene therapy: Adenovirus vectors
2. Gene therapy for cancer: What have we done and where are we going?
3. Replication-selective micro-organisms: Fighting cancer with targeted germ warfare
4. Replication-selective adenviruses as oncolytic agents
5. Experimental therapy of human glioma by means of a genetically engineered virus mutant
6. Replicating oncolytic viruses: An overview
7. Selectively-replicating viruses as therapeutic agents against cancer
8. A novel three-pronged approach to kill cancer cells selectively: Concomitant viral, double suicide gene, and radiotherapy
9. Replicating adenoviral gene therapy
10. Clinical trials: Gene therapy death prompts review of adenovirus vector
11. Gene therapy setback
12. Gene therapy death - Everyone has to share in the guilt
13. Gene therapy on trial
14. Adenovirus proteins from both E1B reading frames are required for transformation of rodent cells by viral infection and DNA transfection
15. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells
16. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents
17. p53-independent and -dependent requirements for E1B-55kD in adenovirus type 5 replication
18. Replication of ONYX-015, a potential anticancer adenovirus, is independent of p53 status in tumor cells
19. p53 status does not determine outcome of E1B 55-kilodalton mutant adenovirus lytic infection
20. In vivo antitumor activity of ONYX-015 is influenced by p53 status and is augmented by radiotherapy
21. ONYX-015: Clinical data are encouraging
22. A phase II trial of intratumoral injection with an E1B-deleted adenovirus, ONYX-015, in patients with recurrent, refractory head and neck cancer
23. Selective replication and oncolysis in p53 mutant tumors with Onyx-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: A phase II trial
24. A controlled trial of Onyx-015, an E1B gene-deleted adenovirus, in combination with chemotherapy in patients with recurrent head and neck cancer
25. A phase II trial of ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer
26. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents
27. A phase I/II trial of ONYX-015 administered by hepatic artery infusion to patients with colorectal carcinoma
28. Intravenous administration of ONYX-015, a selectively-replicating adenovirus, induces antitumoral efficacy
29. Hepatic arterial infusion of chemotherapy following resection of hepatic metastases from colorectal cancer
30. Cancer of the pancreas
31. Urea cycle disorders: Diagnosis, pathophysiology and therapy
32. Identification of a conserved reseptor-binding site on the fiber proteins of CAR-recognizing adenoviridae
33. Recombinant IL-12 prevents formation of blocking IgA antibodies to recombinant adenovirus and allows repeated gene therapy to mouse lung
34. Sero-switch adenovirus-mediated in vivo gene transfer: Circumvention of anti-adenovirus humoral immune defenses against repeat adenovirus vector administration by changing the adenovirus serotype
35. An adenovirus E1A mutant that demonstrates potent and selective antitumoral efficacy
36. Replication-selective adenovirus plus cisplatin chemotherapy efficacy is dependent on sequencing but independent of p53 status
37. Intravenous infusion of a replication-selective adenovirus (Onyx-015) in cancer patients: Safety feasibility and biological activity
38. Adenovirus proteins from both E1B reading frames are required for transformation of rodent cells by viral infection and DNA transfection